Here we have investigated the potential use of human mesenchymal stem cells (MSC) for anticancer therapy of GBM, the most malignant brain tumor. We studied the mutual response of MSC and GBM cells in the indirect cultures in vitro at protein (cytokines) and transcription levels. We identified cytokines, responsible for changed cocultured cells’ phenotype, and revealed upregulated secretion of CCL2/MCP1 cytokine from MSC. Other genes/proteins were identified for the first time to take part in MSC/GBM crosstalk. These results are useful for future gene targeting in cell based anticancer therapy.
In this study we have investigated the interaction of human mesenchymal stem cells (MSCs) and tumor cells, fundamental for MSC’s cellular treatment vectors design. We demonstrated that in gliomas, the recruitment of MSC is driven by glioma-secreted factors. We showed that glioma cells as well as MSCs differentially express connexins by which they interact via gap-junctional coupling to form functional and structural syncytium, which are responsible for cells’ phenotype change. The described phenomena provides new insight into the complexity of interactions between tumor cells and host MSCs.